地拉罗司主要用于治疗什么病症？

Deferasirox dispersible tablets should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Deferasirox dispersible tablets should not be taken together with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet. So, what conditions is Deferasirox mainly used to treat?

Deferasirox was developed by Novartis and was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for Deferasirox (Deferasirox) for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

When taking Deferasirox, some adverse reactions will inevitably occur. Usually these common adverse reactions include: diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine (Creatinine), etc. Other adverse reactions include: increased liver enzymes, cough, throat inflammation, and urticaria. In addition, Deferasirox dispersible tablets should not be taken together with drugs containing aluminum (such as gastric acid neutralizers).

Deferasirox Dose Adjustments: Myelosuppression: Interrupt treatment; may restart once cause of cytopenias is determined; Contraindicated if platelet count <50,000/mm; Cutaneous Toxicity: Rash (severe): Interrupt treatment; may reintroduce at lower doses (with future dose escalations) and short-term oral corticosteroids. Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate. Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding. Hearing loss or visual impairment: Consider dose reduction or treatment interruption.

The above is the content of the indications of Deferasirox, I hope it can help you!